At its meeting on 22 August 2022 the Transparency Council adopted Position No. 80/2022 on the evaluation of drugs: Jardiance (empagliflozin) for the indication: type 2 diabetes mellitus, in patients taking at least one antidiabetic drug, with inadequately controlled diabetes and with very high cardiovascular risk.